References
- Nakazawa G, Finn AV, Ladich E et al. Drug-eluting stent safety: findings from preclinical studies. Expert Rev. Cardiovasc. Ther.6(10), 1379–1391 (2008).
- Kubo T, Imanishi T, Kitabata H et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris a serial optical coherence tomography study. JACC: Cardiovasc. Imag.1(4), 475–484 (2008).
- Ahmed DD, Sobczak SC, Yunginger JW. Occupational allergies caused by latex. Immunol. Allergy Clin. N. Am.23(2), 205–219 (2003).
- Leggat PA, Kedjarune U. Toxicity of methyl methacrylate in dentistry. Int. Dental J.53(3), 126–131 (2003).
- Nakazawa G, Finn AV, Kolodgie FD, Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev. Med. Devices6(1), 33–42 (2009).
- Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol.52(5), 333–342 (2008).
- Stone GW, Midei M, Newman W et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Circulation119(5), 680–686 (2009).
- Meredith IT, Ormiston J, Whitbourn R et al. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am. J. Cardiol.100(8B), 56M-61M (2007).
- Grube E, Hauptmann K, Buellesfeld L, Lim V, Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a biolimus A9 eluting stent with a biogradable polymer coating. Eurointervention1, 53–57 (2005).
- Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS), a randomised non-inferiority trial. Lancet.372(9644), 1163–1173 (2008).
- Togni M, Windecker S, Cocchia R et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol.46(2), 231–236 (2005).
- Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol.51(22), 2123–2129 (2008).
- Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation102(4), 399–404 (2000).
- Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet369(9576), 1869–1875 (2007).
- Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB), a prospective open-label trial. Lancet371(9616), 899–907 (2008).
- Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB), 2-year outcomes and results from multiple imaging methods. Lancet373(9667), 897–910 (2009).
- Nakazawa G, Granada JF, Alviar C et al. Anti-CD34 antibodies immobilized on the surface of sirolimus eluting stents enhance stent endothelialization. J. Am. Coll. Cardiol. Intervent. (2009) (In Press).
- Srivatsa SS, Edwards WD, Boos CM et al. Histologic correlates of angiographic chronic total coronary artery occlusions: influence of occlusion duration on neovascular channel patterns and intimal plaque composition. J. Am. Coll. Cardiol.29(5), 955–963 (1997).
- Vorpahl M, Finn AF, Nakano M, Virmani R. The bioabsorption process: tissue and cellular mechanisms and outcomes. EuroIntervention (2010) (In Press).